You are here: Home > News > News > SIRS-Lab appoints Ed Currie as Executive Vice-President, Corporate Development



SIRS-Lab appoints Ed Currie as Executive Vice-President, Corporate Development

SIRS-Lab appoints Ed Currie as Executive Vice-President, Corporate Development

SIRS-Lab, a leader in molecular diagnostics, is delighted to announce the appointment of Dr. Edward Currie as Executive Vice-President, Corporate Development. In this newly created role, Ed will drive partnering, licensing, companion diagnostics, and corporate business development activities at SIRS-Lab.

Ed Currie, a physician specialized in clinical microbiology and infectious disease, brings 20 years of diagnostic and pharmaceutical industry experience at Eli Lilly, F. Hoffmann-La Roche, IBM, and, most recently, as COO of Kuros BioSurgery. At Roche, as Global Head of Disease Management, Ed created the company’s first integrated Pharma-Diagnostic approach for targeted treatment and personalized medicine.

On his decision to join SIRS-Lab, Ed commented “I am very excited to be joining SIRS-Lab, a highly innovative company that I believe can make a real difference to the outcomes of patients with sepsis and life-threatening infections.”

SIRS-Lab is currently accelerating the clinical routine implementation of its molecular diagnostic suite for sepsis, comprising the products VYOO, the CE approved test for the rapid identification of sepsis-relevant pathogens and resistances, and SIQNATURE, which uses gene expression profiles for the early detection of sepsis. Having established its technological assets, the company has now entered a new growth stage aiming at strong partnerships. This further expansion of the senior management significantly strengthens the company´s abilities in corporate development and B2B activities, whose goals include gaining strategic partnerships for distribution of SIRS-Lab’s diagnostic suite, especially in North America and Asia. The company’s core technologies PUREPROVE, LOOXSTER, and QUICKTUBES will also be available through various licensing models, and there are further partnering opportunities using SIRS-Lab’s profound experience in companion diagnostics and biomarker discovery.

PD Dr Stefan Russwurm, CEO of SIRS-Lab, stated: “We are delighted to welcome Dr. Currie here at SIRS-Lab. His highly regarded wealth of experience and an impressive track-record in the medical and diagnostic area, especially in the field of personalized medicine, will benefit us greatly in expanding our strategic partnerships.”

Sepsis, a main cause of death
Sepsis is a life-threatening systemic infection and one of the main causes of death in hospitals worldwide. Every year, approximately 2 million people suffer from sepsis in the industrialized countries alone. With an average mortality rate of 50%, the disease represents one of the greatest unmet medical needs and is a major burden on healthcare resources.

About SIRS-Lab GmbH
Located in Jena, Germany, SIRS-Lab is a molecular diagnostic company which develops and commercializes unique and innovative products to identify and monitor life-threatening infections such as sepsis, one of the major causes of death in hospitals. With its diagnostic suite consisting of VYOO and SIQNATURE, SIRS-Lab´s molecular diagnostic portfolio meets the currently unmet medical needs of fast and reliable identification and monitoring of sepsis. Created as a spin-off of the University Clinic of Jena, SIRS-Lab was founded in 2000 by S. Russwurm, K. Reinhart, E. Straube, and H.-P. Saluz, and has currently about 50 employees.

Axel Kunz
Manager Public Relations
Tel.: +49 (0) 3641 508 430


Document Actions